Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: A study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party

Andrea Necchi, Rosalba Miceli, Marco Bregni, C. Bokemeyer, L. A. Berger, K. Oechsle, K. Schumacher, E. Kanfer, J. H. Bourhis, C. Massard, Daniele Laszlo, Juan Bautista Montoro Gomez, A. Fléchon, F. Arpaci, Simona Secondino, P. Wuchter, P. Dreger, M. Crysandt, N. Worel, W. KrugerMark Ringhoffer, A. Unal, Arnon Nagler, A. Campos, A. Wahlin, Mariagrazia Michieli, G. Sucak, I. Donnini, R. Schots, Norbert Ifrah, Manuela Badoglio, M. Martino, D. Raggi, Patrizia Giannatempo, G. Rosti, Paolo Pedrazzoli, F. Lanza

Research output: Contribution to journalArticle

Abstract

Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced germ cell tumors. Twenty European Society for Blood and Marrow Transplantation centers contributed data on patients treated between 2002 and 2012. Paclitaxel used in either prior lines of therapy or in induction-mobilization regimens was considered. Multivariable Cox analyses of prespecified factors were undertaken on PFS and overall survival (OS). As of October 2013, data for 324 patients had been contributed to this study. One hundred and ninety-two patients (59.3%) had received paclitaxel. Sixty-one patients (19%) had a progression to induction chemotherapy, 234 (72%) a response (29 (9%) missing or granulocyte colony-stimulating factor without chemotherapy). Both progression to induction chemotherapy and prior paclitaxel were significantly associated with shorter OS univariably (P

Original languageEnglish
Pages (from-to)384-390
Number of pages7
JournalBone Marrow Transplantation
Volume51
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: A study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party'. Together they form a unique fingerprint.

  • Cite this